Zenas BioPharma, Inc.
obexelimab
Immunoglobulin G4-Related Disease (IgG4-RD)
Resolved
157days ago
Phase 3 readout · ~ Jan 31, 2026 estimated
What's at stake
Phase 3 trial results for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) are due ~ Jan 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Reported positive results from the Phase 3 INDIGO registrational trial of obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD) in January 2026”